Toll Free: 1-888-928-9744

Botulism - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 34 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Botulism - Pipeline Review, H1 2015


Global Markets Direct's, 'Botulism - Pipeline Review, H1 2015', provides an overview of the Botulism's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Botulism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Botulism and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- The report provides a snapshot of the global therapeutic landscape of Botulism
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Botulism and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Botulism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Botulism pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Botulism
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Botulism pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Botulism Overview 6
Therapeutics Development 7
Pipeline Products for Botulism - Overview 7
Pipeline Products for Botulism - Comparative Analysis 8
Botulism - Therapeutics under Development by Companies 9
Botulism - Pipeline Products Glance 10
Early Stage Products 10
Botulism - Products under Development by Companies 11
Botulism - Companies Involved in Therapeutics Development 12
AlphaVax, Inc. 12
Hawaii Biotech, Inc. 13
Microbiotix, Inc. 14
Molecular Targeting Technologies, Inc. 15
Planet Biotechnology Inc. 16
Botulism - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 19
Assessment by Molecule Type 20
Drug Profiles 22
Botulinum Neurotoxin Vaccine (Multivalent) - Drug Profile 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
botulinum toxin vaccine - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
botulinum vaccine - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Botulism Vaccine - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Monoclonal Antibodies to Inhibit Botulinum Neurotoxin for Botulism - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Recombinant Peptides to Inhibit Botulinum Toxin for Botulism - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Small Molecules for Botulism - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Small Molecules to Inhibit BoNT/A LC for Botulism - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Botulism - Dormant Projects 31
Botulism - Discontinued Products 32
Appendix 33
Methodology 33
Coverage 33
Secondary Research 33
Primary Research 33
Expert Panel Validation 33
Contact Us 34
Disclaimer 34
List of Tables
Number of Products under Development for Botulism, H1 2015 7
Number of Products under Development for Botulism - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Early Stage Development, H1 2015 10
Products under Development by Companies, H1 2015 11
Botulism - Pipeline by AlphaVax, Inc., H1 2015 12
Botulism - Pipeline by Hawaii Biotech, Inc., H1 2015 13
Botulism - Pipeline by Microbiotix, Inc., H1 2015 14
Botulism - Pipeline by Molecular Targeting Technologies, Inc., H1 2015 15
Botulism - Pipeline by Planet Biotechnology Inc., H1 2015 16
Assessment by Monotherapy Products, H1 2015 17
Number of Products by Stage and Target, H1 2015 18
Number of Products by Stage and Mechanism of Action, H1 2015 19
Number of Products by Stage and Molecule Type, H1 2015 21
Botulism - Dormant Projects, H1 2015 31
Botulism - Discontinued Products, H1 2015 32 

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.